Phasiq, an Ann Arbor proteomics startup, just received a pre-seed round of funding from the student-run Zell Lurie commercialization fund at the University of Michigan, it said a statement.
Phasiq is developing a multiplex assay that’s meant to quickly and inexpensively identify several proteins in a sample. It could be used in multiple disease diagnostics and for drug development. The funding will be used to automate its manufacturing process to make production scalable for its assay.
The company, founded in 2012, plans to launch its assay commercially next year. Read about how its multiplexing technology works here.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The underlying research comes from University of Michigan professor Shuichi Takayama, who works in the field of macromolecular science and biomedical engineering.
